From Diagnosis to Immunotherapy: Translational Pathways and Bottlenecks of Organic Luminescent Materials in Urothelial Carcinoma
Molecules · 19.11.2026 · 31 (22) · 4195
DOI: 10.3390/molecules31224195 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 19.11.2026. Verfasst von Sheng Zeng und 6 weiteren Autor:innen. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianjin Natural Science Foundation, National Natural Science Foundation of China, Tianjin Key Medical Discipline (Specialty) Construction.
Abstract (Originalsprache)
Bladder cancer (BCa) and upper tract urothelial carcinoma (UTUC) share three stubborn clinical problems: carcinoma in situ (CIS) is hard to find, residual lesions after transurethral resection of bladder tumor (TURBT) are easy to miss, and patients who do not respond to bacillus Calmette–Guérin (BCG) have few effective bladder-sparing options. The bladder and ureter are natural lumens that endoscopy can reach, which gives us an anatomical foothold for combining molecular detection, intraoperative navigation, and local therapy. This review follows how organic luminescent materials have moved from photodynamic diagnosis (PDD) to photoimmunotherapy (PIT), and looks at where clinical translation currently stands and what still blocks it. PDD improves CIS detection—several clinical studies support this—but false positives and the poor tissue penetration of blue light keep its use narrow. In the first-in-human trial of a Nectin-4-targeted fluorescent probe, biopsy diagnostic accuracy reached 96.0%, a sign that molecular imaging-guided surgery has entered clinical validation. On the therapeutic side, antibody–photoabsorber conjugates can selectively kill membrane-marker-positive tumor cells, and when paired with immune checkpoint inhibitors, they show promise in BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). Insufficient tissue penetration, limited target specificity, and the absence of standardized light dosimetry remain the core barriers to translation. NIR-II imaging and activatable theranostic agents are likely to be the most important future directions.
Förderung
- Tianjin Natural Science Foundation
- National Natural Science Foundation of China
- Tianjin Key Medical Discipline (Specialty) Construction
- Tianjin Health Science and Technology Project
Zitieren
APA
Zeng, S., Guo, J., Wang, M., Chen, P., Xue, S., Yang, Z., & Liu, Q. (2026). From Diagnosis to Immunotherapy: Translational Pathways and Bottlenecks of Organic Luminescent Materials in Urothelial Carcinoma. Molecules, 31(22), 4195. https://doi.org/10.3390/molecules31224195
Vancouver
Zeng S, Guo J, Wang M, Chen P, Xue S, Yang Z, et al. From Diagnosis to Immunotherapy: Translational Pathways and Bottlenecks of Organic Luminescent Materials in Urothelial Carcinoma. Molecules. 2026;31(22):4195. doi:10.3390/molecules31224195
BibTeX
@article{Zeng2026,
author = {Zeng, Sheng and Guo, Jinke and Wang, Minze and Chen, Pengyu and Xue, Shilong and Yang, Zhanpo and Liu, Qian},
title = {From Diagnosis to Immunotherapy: Translational Pathways and Bottlenecks of Organic Luminescent Materials in Urothelial Carcinoma},
journal = {Molecules},
year = {2026},
volume = {31},
number = {22},
pages = {4195},
doi = {10.3390/molecules31224195}
}
EUVIMED